INTRODUCTION
============

Type I trichorhinophalangeal syndrome (TRPS) presents with craniofacial dysmorphism, skeletal abnormality, and sparse scalp hairs[@B1]. TRPS patients tend to have alopecia that appears to be androgenetic, and thus, this genetic model might give clues to the pathogenesis of hair loss or hair morphogenesis, as has been found in previous studies[@B2]. Fantauzzo and Christiano[@B1] reported that the target genes of Trps1, Wif1, Sox18, and Sox21 played an important role in vibrissa follicle morphogenesis by analyzing the gene expression profiles between wild-type and Trps1Δgt/Δgt mutant mouse embryos to understand hair morphogenesis. This is very interesting because sparse scalp hair is a common feature of TRPS. Herein, we analyzed whole transcriptome from non-balding and balding scalp areas from the TRPS patient using high-throughput sequencing and attempted to identify important genetic information about TRPS symptoms and hair morphogenesis.

MATERIALS AND METHODS
=====================

Information of patient with TRPS type I
---------------------------------------

A 15-year-old boy visited with sparse and slowly growing scalp hairs that had been that way since his childhood. Especially, his fronto-temporal hair line regressed to the vertex and his vertex hair density and thickness decreased compared to the occiput hairs. He had the typical TRPS phenotypes, including a bulbous nose, a long philtrum, and abnormally short fingers and toes. We took tissue from the non-balding (occiput area) and balding portions (vertex area) of his scalp for genetic analysis ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). This study was approved by the institutional review board of Dankook University Hospital (IRB no. DKUH 2014-08-005).

RNA sequencing
--------------

We extracted total RNA from the tissues using trizol reagent, and then enriched mRNA by oligo-dT and synthesized to cDNA. We subjected the cDNA to end-repair and poly-A addition and connected it with 5′ and 3′adaptors on both ends[@B3]. By separating on a BluePippin 2% agarose gel (Sage Science, Beverly, MA, USA), we selected and amplified suitable fragments. The final library sizes and qualities were evaluated with an Agilent High Sensitivity DNA kit (Agilent Technologies, Santa Clara, CA, USA). Subsequently, we performed high-throughput RNA sequencing using an Illumina Hiseq2500 sequencer (Illumina, San Diego, CA, USA). Among total output reads, we mapped high-quality reads to the human reference genome (Ensembl release 72)[@B4].

Differentially expressed genes and gene ontology analysis
---------------------------------------------------------

We calculated the gene expression level based on fragments per kilobase of exon per million mapped reads (FPKM) using Cufflinks v2.1.13 from Ensembl release 72. We generated gene-level count data using HTSeq-count v0.5.4p3[@B5]. Based on this, we analyzed differentially expressed genes (DEGs) using the gene TCC[@B6]. We calculated normalization factors using iterative DEGES/edgeR. We filtered DEGs based on *p*-value \<0.05 and log2 fold change \>0. To characterize their molecular function, we analyzed gene ontology (GO) ([www.geneontology.org](www.geneontology.org)). *p*-value \<0.001 was considered statistically significant.

Quantitative real-time polymerase chain reaction
------------------------------------------------

We synthesized a total of 500 ng of RNA to cDNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA) and an RNase inhibitor (Promega). We designed a primer pair for target genes using Primer 3 (<http://bioinfo.ut.ee/primer3-0.4.0/primer3/>) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). We amplified 15 genes and a *GAPDH* gene as a control to normalize expression using the Eco Real-Time PCR System (Illumina). We confirmed the absence of any non-specific amplified products through melting curve analysis at 55℃\~95℃. All reactions were performed in triplicate and analyzed by delta-delta Ct method.

RESULTS
=======

Dataset from RNA sequencing
---------------------------

We processed a total of ten billion raw reads in the filtering step and mapped 94.9% and 94.8% of the clean reads on the human reference genome ([Table 1](#T1){ref-type="table"}). Based on these data, we found a total of 26,320 genes, which comprised 14,892 known genes with new isoforms and 4,883 novel genes. At the transcript level, we found a total of 218,609 transcripts expressed (FPKM \>0) in either the non-balding and balding scalps.

Identifying differentially expressed genes
------------------------------------------

Based on FPKM value, we analyzed gene expression levels and identified DEGs between the non-balding and balding scalp samples. The total number of DEGs was 1,242, comprising transcripts expressed in both samples and in either sample (with *p*-value \<0.05 and log2 fold-change \>0) ([Fig. 1](#F1){ref-type="fig"}). Compared to non-balding sample, up- and down-regulated genes were 636 and 606 in balding scalp; specifically, 557 genes showed sample-specific expression.

Gene ontology analysis
----------------------

To characterize the DEGs, we conducted GO analysis. A total of 1,242 DEGs were associated with 3,108 GO terms; at the cut-off of *p*-value \<0.001, 45, 17 and 11 GO terms were associated with biological processes, molecular function, and cellular components, respectively ([Supplementary Table 2](#S3){ref-type="supplementary-material"}, [3](#S4){ref-type="supplementary-material"}). The hair-related terms were follicle morphogenesis and development, the hair cycle, hair cell differentiation, and keratinization and were associated with the down-regulated *SOX21* gene.

Verifying DEGs using quantitative real-time polymerase chain reaction
---------------------------------------------------------------------

We validated 15 DEGs in the non-balding and balding scalps samples using quantitative real-time polymerase chain reaction ([Supplementary Table 1](#S2){ref-type="supplementary-material"}), preferentially selecting skin, hair, and alopecia-related genes; in addition, we validated the *WIF1*, *SOX21*, *TINAG* and *TRPS1* genes studied in TRPS1Δgt/Δgt mutant mouse[@B1]. Additionally, we validated *HBA2*, *GAL*, *DES* (the up-regulated genes with the lowest *p*-values) and *PTGDS*, and this result was consistent with the RNA sequencing ([Fig. 2](#F2){ref-type="fig"}). Thirteen of the 15 genes were statistically significant (*p*\<0.01), including six genes with *p*-value \<0.001. The *SOX21* and *PTGDS* genes were down-regulated but not significantly (*p*\>0.05).

DISCUSSION
==========

Interestingly, the sparse hairs of TRPS patients are thin and miniaturized just as in androgenic alopecia. Therefore, we intended to find a genetic difference the between non-balding and balding scalp of a TRPS type I patient and identify a candidate genes related to hair loss or morphogenesis. Among 1,242 of DEGs, we could find lots of keratin and keratin associated genes which might be due to sampling from scalps. Two keratin-related genes (*KRT6C* and *KRTAP3-1*) were down-regulated in balding scalp. The *MKI67* down-regulated in balding scalp is involved in active proliferation of cells and are reported low expression in hair follicle stem cells[@B7]. Down-regulation of *MKI67* in balding scalp of TRPS type I patient in our study seemed to suggest degenerated or abnormal hair cell cycle.

A key factor in TRPS pathogenesis, the *TRPS1* gene was down-regulated in the balding area. Originally, TRPS1 is a transcription factor to repress its target genes via binding to GATA motif of the promoter region[@B1]. However, a recent study has revealed that *TRPS1* activated the expression of target gene. Fantauzzo and Christiano[@B1] showed *Trps1* activated Wnt inhibitors and other transcription factor essential for follicle morphogenesis in mouse. Study of a TRPS mutant mouse suggests that TRPS1 might be necessary for hair follicular formation and shows that the Wnt inhibitor and extracellular matrix protein were regulated by TRPS1 during early hair morphogenesis[@B8]. Decreased TRPS1 protein can disrupt endochondral cartilage differentiation and cell interactions in hair follicle development[@B9]. In addition, TRPS1 protein expression is down-regulated by androgens in human prostate cancer, and thus the *TRPS1* gene might play a role in androgen metabolism in prostate cancer[@B10]. Though the correlation of *TRPS1* gene and androgen metabolism has not yet been studied in the alopecia, we could expect the further study about this correlation because the male pattern baldness is associated with androgen metabolism.

*WIF1* and *SOX21*, the target genes of TRPS1, were down-regulated in a TRPS1Δgt/Δgt mutant mouse and in the balding scalp of a TRPS type I patient[@B1]. *WIF1* is a Wnt inhibitor and is expressed in dermal papilla, like *TRPS1* gene. In a previous study, Wnt-related genes including WNT11 and WIF1 were up-regulated in a 120-day-old goat embryo in which secondary hair follicles and mature primary hair follicles were present, which indicates that Wnt signaling is involved in early hair follicle formation[@B11]. The *SOX21* gene was shown to regulate the layered differentiation of hair follicles[@B12]. Its disruption showed the human alopecia-like phenotype in a mouse with progressive hair loss. Interestingly, target gene expression in TRPS was not inversely proportional to that in Fantauzzo\'s TRPS1 Δgt/Δgt mutant mouse[@B1].

We compared the gene expression patterns with those of androgenetic alopecia by Garza et al.[@B13]. *KRT6C* and *GPRC5D* were down-regulated and the *HBA2* gene was up-regulated in balding scalp in both studies. However, *PTGDS* expression was not significant, unlike in a previous study[@B13]. The *GPRC5D* gene was dramatically up-regulated in hair follicle keratinization and differentiation in the skin of an old embryo (120-day) in which secondary hair follicles had developed and primary hair follicles had matured, indicating its role in keratinization and hair follicle morphogenesis[@B11]. PTGDS might be involved in androgenetic alopecia[@B13], but it is not related to hair loss in TRPS.

In conclusion, we expect our results to suggest novel perspectives and support further study to understand TRPS and hair morphogenesis.
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SUPPLEMENTARY MATERIALS
=======================

Supplementary data can be found via <http://anndermatol.org/src/sm/ad-29-597-s001.pdf>.

###### Supplementary Fig. 1

Photograph of the trichorhinophalangeal syndrome patient. He has sparse and slowly growing scalp hairs (up), bulbous nose, long philtrum, and thin upper lip (bottom). A red circle indicates vertex area where tissue was obtained but, occiput is not appeared in this photograph.

###### Supplementary Table 1

Information of primer pairs used in quantitative real-time polymerase chain reaction

###### Supplementary Table 2

DEGs and GO

###### Supplementary Table 3

Go terms

![Heat map of differently expressed genes in the non-balding and balding scalp samples. A total of 1,242 differentially expressed genes (DEGs) were identified through RNA sequencing (*p*-value \<0.01 and log2 fold-change \>0). The left and right columns display, respectively, the results for the non-balding and balding scalp areas. Up-regulated to down-regulated genes are indicated by red and yellow, respectively.](ad-29-597-g001){#F1}

![Validation of 15 differentially expressed genes by quantitative real-time polymerase chain reaction. Three genes were up-regulated (green bar) and 12 were down-regulated (blue bar) in the non-balding scalp. Thirteen genes showed statistical significance (*p*-value\<0.05); the exceptions were *SOX21* and *PTGDS*. (^\*\*^*p*\<0.01, and ^\*\*\*^*p*\<0.001).](ad-29-597-g002){#F2}

###### Summary of RNA-sequencing

![](ad-29-597-i001)

  Sample       Raw reads    Clean reads (%)     Mapped reads (%)    Properly paired (%)   Gene     Transcript                                        
  ------------ ------------ ------------------- ------------------- --------------------- -------- ------------ -------- ------- --------- --------- --------
  Nonbalding   53,351,054   50,338,798 (94.4)   47,780,868 (94.9)   36,570,528 (72.6)     26,320   3,426        14,892   4,883   218,609   150,194   68,415
  Balding      54,289,736   51,192,244 (94.3)   48,539,550 (94.8)   36,789,924 (71.9)                                                                
